• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Pembrolizumab for first-line mRCC: Anecdotal evidence in real-world setting


Arjun V. Balar, MD, discusses combination treatment with pembrolizumab (Keytruda) and axitinib (Inlyta) in the first-line setting for metastatic RCC.

In this video, Arjun V. Balar, MD, discusses the use of the immune checkpoint inhibitor pembrolizumab (Keytruda) for the treatment of metastatic renal cell carcinoma. Balar is associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.